New Jersey Pharmaceutical Companies Support NJ Medicare Resolution
New Brunswick, NJ, October 1, 2001 — New Jersey’s pharmaceutical companies support New Jersey Senate Concurrent Resolution 116, which calls for Congress to enact legislation to provide prescription drug coverage for Medicare recipients without penalizing states, such as New Jersey, that have their own pharmaceutical assistance programs for their elderly residents.
Former New Jersey Congressman Bob Franks Named President of HealthCare Institute of New Jersey
New Brunswick, NJ, July 5, 2001 — Former New Jersey Congressman Bob Franks has been appointed President of the HealthCare Institute of New Jersey, the organization’s Board of Trustees announced today. Mr. Franks assumes this position August 1, succeeding William H. Tremayne, who is retiring.
PricewaterhouseCoopers Study: New Jersey Pharmaceutical Companies Lead in Drugs in Development
New Brunswick, NJ, February 26, 2001 — New Jersey’s pharmaceutical companies are developing approximately one-third of all new products and indications now in clinical trials and awaiting FDA approval. In addition, New Jersey-based pharmaceutical and medical technology companies are showing significant increases in employment and capital investment.
New Jersey Continued to Lead Nation in FDA’s New Drug Approvals in 2000
New Brunswick, NJ, January 18, 2001 — Nearly 40 per cent of the U.S. Food and Drug Administration (FDA) approvals for new medicines in 2000 were given to research-based pharmaceutical companies headquartered in New Jersey.